Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 100

1.

Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment.

Bock N, Shokoohmand A, Kryza T, Röhl J, Meijer J, Tran PA, Nelson CC, Clements JA, Hutmacher DW.

Bone Res. 2019 Apr 25;7:13. doi: 10.1038/s41413-019-0049-8. eCollection 2019.

2.

Lipid Uptake Is an Androgen-Enhanced Lipid Supply Pathway Associated with Prostate Cancer Disease Progression and Bone Metastasis.

Tousignant KD, Rockstroh A, Taherian Fard A, Lehman ML, Wang C, McPherson SJ, Philp LK, Bartonicek N, Dinger ME, Nelson CC, Sadowski MC.

Mol Cancer Res. 2019 May;17(5):1166-1179. doi: 10.1158/1541-7786.MCR-18-1147. Epub 2019 Feb 26.

PMID:
30808729
3.

Correction: A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome.

Stylianou N, Lehman ML, Wang C, Fard AT, Rockstroh A, Fazli L, Jovanovic L, Ward M, Sadowski MC, Kashyap AS, Buttyan R, Gleave ME, Westbrook TF, Williams ED, Gunter JH, Nelson CC, Hollier BG.

Oncogene. 2019 Mar;38(13):2436. doi: 10.1038/s41388-018-0587-3.

PMID:
30510231
4.

No effect of unacylated ghrelin administration on subcutaneous PC3 xenograft growth or metabolic parameters in a Rag1-/- mouse model of metabolic dysfunction.

Maugham ML, Seim I, Thomas PB, Crisp GJ, Shah ET, Herington AC, Brown KA, Gregory LS, Nelson CC, Jeffery PL, Chopin LK.

PLoS One. 2018 Nov 20;13(11):e0198495. doi: 10.1371/journal.pone.0198495. eCollection 2018.

5.

Limited short-term effects on human prostate cancer xenograft growth and epidermal growth factor receptor gene expression by the ghrelin receptor antagonist [D-Lys3]-GHRP-6.

Maugham ML, Seim I, Thomas PB, Crisp GJ, Shah ET, Herington AC, Gregory LS, Nelson CC, Jeffery PL, Chopin LK.

Endocrine. 2018 Nov 2. doi: 10.1007/s12020-018-1796-9. [Epub ahead of print]

PMID:
30390209
6.

A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome.

Stylianou N, Lehman ML, Wang C, Fard AT, Rockstroh A, Fazli L, Jovanovic L, Ward M, Sadowski MC, Kashyap AS, Buttyan R, Gleave ME, Westbrook TF, Williams ED, Gunter JH, Nelson CC, Hollier BG.

Oncogene. 2019 Feb;38(7):913-934. doi: 10.1038/s41388-018-0488-5. Epub 2018 Sep 7. Erratum in: Oncogene. 2018 Dec 3;:.

PMID:
30194451
7.

Transcriptomic analysis of mRNA expression and alternative splicing during mouse sex determination.

Zhao L, Wang C, Lehman ML, He M, An J, Svingen T, Spiller CM, Ng ET, Nelson CC, Koopman P.

Mol Cell Endocrinol. 2018 Dec 15;478:84-96. doi: 10.1016/j.mce.2018.07.010. Epub 2018 Jul 24.

PMID:
30053582
8.

Mining human cancer datasets for kallikrein expression in cancer: the 'KLK-CANMAP' Shiny web tool.

Wang C, Moya L, Clements JA, Nelson CC, Batra J.

Biol Chem. 2018 Sep 25;399(9):983-995. doi: 10.1515/hsz-2017-0322.

PMID:
30052511
9.

Identification of Gibberellic Acid Derivatives That Deregulate Cholesterol Metabolism in Prostate Cancer Cells.

Egbewande FA, Sadowski MC, Levrier C, Tousignant KD, White JM, Coster MJ, Nelson CC, Davis RA.

J Nat Prod. 2018 Apr 27;81(4):838-845. doi: 10.1021/acs.jnatprod.7b00929. Epub 2018 Feb 23.

PMID:
29474071
10.

A microsatellite repeat in PCA3 long non-coding RNA is associated with prostate cancer risk and aggressiveness.

Lai J, Moya L, An J, Hoffman A, Srinivasan S, Panchadsaram J, Walpole C, Perry-Keene JL, Chambers S; Australian Prostate Cancer BioResource, Lehman ML, Nelson CC, Clements JA, Batra J.

Sci Rep. 2017 Dec 4;7(1):16862. doi: 10.1038/s41598-017-16700-y.

11.

Extracellular Vesicles in the Adaptive Process of Prostate Cancer during Inhibition of Androgen Receptor Signaling by Enzalutamide.

Soekmadji C, Rockstroh A, Ramm GA, Nelson CC, Russell PJ.

Proteomics. 2017 Dec;17(23-24). doi: 10.1002/pmic.201600427.

PMID:
29105980
12.

Folate-targeted amphiphilic cyclodextrin nanoparticles incorporating a fusogenic peptide deliver therapeutic siRNA and inhibit the invasive capacity of 3D prostate cancer tumours.

Evans JC, Malhotra M, Sweeney K, Darcy R, Nelson CC, Hollier BG, O'Driscoll CM.

Int J Pharm. 2017 Oct 30;532(1):511-518. doi: 10.1016/j.ijpharm.2017.09.013. Epub 2017 Sep 13.

PMID:
28916296
13.

Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer.

Soekmadji C, Riches JD, Russell PJ, Ruelcke JE, McPherson S, Wang C, Hovens CM, Corcoran NM; Australian Prostate Cancer Collaboration BioResource, Hill MM, Nelson CC.

Oncotarget. 2016 Aug 8;8(32):52237-52255. doi: 10.18632/oncotarget.11111. eCollection 2017 Aug 8.

14.

Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.

Soekmadji C, Corcoran NM, Oleinikova I, Jovanovic L; Australian Prostate Cancer Collaboration BioResource, Ramm GA, Nelson CC, Jenster G, Russell PJ.

Prostate. 2017 Oct;77(14):1416-1423. doi: 10.1002/pros.23403. Epub 2017 Aug 29. Review.

PMID:
28856701
15.

Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells.

Levrier C, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, Davis RA, Sadowski MC, Nelson CC.

Cell Cycle. 2018;17(5):652-668. doi: 10.1080/15384101.2017.1356512.

16.

Whole-Genome Sequence of the Metastatic PC3 and LNCaP Human Prostate Cancer Cell Lines.

Seim I, Jeffery PL, Thomas PB, Nelson CC, Chopin LK.

G3 (Bethesda). 2017 Jun 7;7(6):1731-1741. doi: 10.1534/g3.117.039909.

17.

Insights from engraftable immunodeficient mouse models of hyperinsulinaemia.

Maugham ML, Thomas PB, Crisp GJ, Philp LK, Shah ET, Herington AC, Chen C, Gregory LS, Nelson CC, Seim I, Jeffery PL, Chopin LK.

Sci Rep. 2017 Mar 28;7(1):491. doi: 10.1038/s41598-017-00443-x.

18.

6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells.

Levrier C, Sadowski MC, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, Davis RA, Nelson CC.

Mol Cancer Ther. 2017 Jan;16(1):3-15. doi: 10.1158/1535-7163.MCT-16-0325. Epub 2016 Oct 19.

19.

Short term ex-vivo expansion of circulating head and neck tumour cells.

Kulasinghe A, Perry C, Warkiani ME, Blick T, Davies A, O'Byrne K, Thompson EW, Nelson CC, Vela I, Punyadeera C.

Oncotarget. 2016 Sep 13;7(37):60101-60109. doi: 10.18632/oncotarget.11159.

20.

Erratum to: Fusion transcript loci share many genomic features with non-fusion loci.

Lai J, An J, Seim I, Walpole C, Hoffman A, Moya L, Srinivasan S, Perry-Keene JL; Australian Prostate Cancer Bioresource, Wang C, Lehman ML, Nelson CC, Clements JA, Batra J.

BMC Genomics. 2016 Jun 3;17(1):424. No abstract available.

Supplemental Content

Loading ...
Support Center